- Home
- AEYE vs ENTA Comparison
AEYE vs ENTA Comparison
Compare AEYE & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEYE
- ENTA
- Stock Information
- Founded
- AEYE 2005
- ENTA 1995
- Country
- AEYE United States
- ENTA United States
- Employees
- AEYE N/A
- ENTA N/A
- Industry
- AEYE Computer Software: Prepackaged Software
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- AEYE Technology
- ENTA Health Care
- Exchange
- AEYE Nasdaq
- ENTA Nasdaq
- Market Cap
- AEYE 164.9M
- ENTA 164.6M
- IPO Year
- AEYE N/A
- ENTA 2013
- Fundamental
- Price
- AEYE $13.00
- ENTA $11.01
- Analyst Decision
- AEYE Strong Buy
- ENTA Strong Buy
- Analyst Count
- AEYE 4
- ENTA 5
- Target Price
- AEYE $25.25
- ENTA $21.00
- AVG Volume (30 Days)
- AEYE 96.0K
- ENTA 1.6M
- Earning Date
- AEYE 11-06-2025
- ENTA 11-24-2025
- Dividend Yield
- AEYE N/A
- ENTA N/A
- EPS Growth
- AEYE N/A
- ENTA N/A
- EPS
- AEYE N/A
- ENTA N/A
- Revenue
- AEYE $38,238,000.00
- ENTA $64,806,000.00
- Revenue This Year
- AEYE $17.16
- ENTA $0.07
- Revenue Next Year
- AEYE $14.79
- ENTA N/A
- P/E Ratio
- AEYE N/A
- ENTA N/A
- Revenue Growth
- AEYE 18.53
- ENTA N/A
- 52 Week Low
- AEYE $8.91
- ENTA $4.09
- 52 Week High
- AEYE $34.85
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- AEYE 42.16
- ENTA 54.52
- Support Level
- AEYE $13.57
- ENTA $10.87
- Resistance Level
- AEYE $14.50
- ENTA $12.02
- Average True Range (ATR)
- AEYE 0.75
- ENTA 1.03
- MACD
- AEYE -0.20
- ENTA -0.03
- Stochastic Oscillator
- AEYE 7.87
- ENTA 20.27
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.